Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Protease Assays

Guofeng Zhang  1
Sarine Markossian  1 , Abigail Grossman  1 , Hannah Baskir  1 , Michelle Arkin  2 , Douglas Auld  3 , Christopher Austin  4 , Jonathan Baell  5 , Kyle Brimacombe  1 , Thomas D.Y. Chung  6 , Nathan P. Coussens  7 , Jayme L. Dahlin  8 , Viswanath Devanarayan  9 , Timothy L. Foley  10 , Marcie Glicksman  11 , Kirill Gorshkov  12 , Stefan Grotegut  13 , Matthew D. Hall  1 , Samuel Hoare  14 , James Inglese  1 , Philip W. Iversen  15 , Madhu Lal-Nag  16 , Zhuyin Li  12 , Jason R. Manro  13 , James McGee  17 , Allison Norvil  13 , Mackenzie Pearson  13 , Terry Riss  18 , Peter Saradjian  19 , G. Sitta Sittampalam  20 , Michael A. Tarselli  21 , O. Joseph Trask Jr.  22 , Jeffrey R. Weidner  23 , Mary Jo Wildey  24 , Kelli Wilson  1 , Menghang Xia  1 , Xin Xu  1
, editors.
In: Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.
[updated ].
Affiliations
Free Books & Documents
Review

Protease Assays

Guofeng Zhang.
Free Books & Documents

Excerpt

Proteases are important drug targets; the first drugs to reach the market were antihypertensives and antivirals. Designing HTS assays for these targets requires thorough understanding of the biochemistry and biology of these enzymes as well as various assay formats. In this chapter, the authors present basic properties of protease enzymes, sensitive fluorescent assay formats compatible with HTS, both in homogeneous and separation-based approaches. Sections on hit selection and data analysis concepts for identifying inhibitors are also included with an extensive set of literature references.

PubMed Disclaimer

References

    1. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006;5(9):785–99. - PubMed
    1. Chen D., et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11(3):239–53. - PMC - PubMed
    1. Zhu Z., Cuozzo J. Review article: high-throughput affinity-based technologies for small-molecule drug discovery. J Biomol Screen. 2009;14(10):1157–64. - PubMed
    1. Mayr L.M., Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009;9(5):580–8. - PubMed
    1. Zimmerman M., Yurewicz E., Patel G. A new fluorogenic substrate for chymotrypsin. Anal Biochem. 1976;70(1):258–62. - PubMed

LinkOut - more resources